RVA-induced necrosome formation consisting of RIPK1, RIPK3, and MLKL

Blunted Fas signaling favors RIPK1-driven neutrophil necroptosis in critically ill COVID-19 patients

MLKL in cancer: more than a necroptosis regulator. - Abstract - Europe PMC

MLKL in cancer: more than a necroptosis regulator. - Abstract - Europe PMC

Uncovering human mixed lineage kinase domain-like activation in necroptosis

Epigenetic Silencing of RIPK3 in Hepatocytes Prevents MLKL-mediated Necroptosis From Contributing to Liver Pathologies - Gastroenterology

Necroptosis molecular mechanisms: Recent findings regarding novel necroptosis regulators

Loss of MLKL (Mixed Lineage Kinase Domain-Like Protein) Decreases Necrotic Core but Increases Macrophage Lipid Accumulation in Atherosclerosis

MLKL in cancer: more than a necroptosis regulator. - Abstract - Europe PMC

Frontiers Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia

Double agents of cell death: novel emerging functions of apoptotic regulators - Lamb - 2020 - The FEBS Journal - Wiley Online Library

Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia, Journal of Experimental & Clinical Cancer Research

RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review)

Shikonin overcomes drug resistance and induces necroptosis by regulating the miR-92a-1-5p/MLKL axis in chronic myeloid leukemia